Teva Pharmaceutical Industries Limited (NYSE:TEVA) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participants trying to figure out its next move. Now trading with a market value of 24.14B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.Teva Pharmaceutical Industries Limited (NYSE:TEVA) Fundamentals That Matter
It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For TEVA, the company currently has 1.86 billion of cash on the books, which is offset by 2.92 billion in current liabilities. The trend over time is important to note. In this case, the company’s debt has been falling. The company also has 0 in total assets, balanced by 2.86 billion in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.
Teva Pharmaceutical Industries Limited saw 0 in free cash flow last quarter, representing a quarterly net change in cash of 1.36 billion. Perhaps most importantly where cash movements are concerned, the company saw about 0 in net operating cash flow.Teva Pharmaceutical Industries Limited (NYSE:TEVA) Revenue Growth Potential
As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 4.7 billion in total revenues. That represents a quarterly year/year change in revenues of -0.22% in sequential terms, the TEVA saw sales grow by -0.08%.
But what about the bottom line? After all, that’s what really matters in the end. Teva Pharmaceutical Industries Limited is intriguing when broken down to its core data. The cost of selling goods last quarter was 2.64 billion, yielding a gross basic income of 2.06 billion. For shareholders, given the total diluted outstanding shares of 1.05B, this means overall earnings per share of -160. Note, this compares with a consensus analyst forecast of 0.50 in earnings per share for its next fiscal quarterly report.Is Teva Pharmaceutical Industries Limited (NYSE:TEVA) Valuation Attractive
Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 2.73 in total earnings per share. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Teva Pharmaceutical Industries Limited.